BMS Korea Diabetes Drugs Lead Planned Launch Of Six New Products
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb plans to launch six new innovative drugs in South Korea in the next two years, beginning with its Kombiglyze XR , a diabetes drug combining Onglyza (saxagliptin) and Glucophage (metformin).